MedTrace Logo

Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients

NCT05311852 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-09-26

No results posted yet for this study

Summary

The study explore the efficacy of PEA-LUT in patients suffering from neurological symptoms of Long-Covid

Conditions

Interventions

DIETARY_SUPPLEMENT

palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)

assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks

DIETARY_SUPPLEMENT

Placebo

assumption of a placebo product 2 time/day for 8 weeks

Sponsors & Collaborators

  • I.R.C.C.S. Fondazione Santa Lucia

    collaborator OTHER

  • Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy

    lead NETWORK

Principal Investigators

  • Leopold Saltuari, Md · Department of Neurorehabiliation - Hospital of Vipiteno-Sterzing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-16
Primary Completion
2022-02-15
Completion
2022-03-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05311852 on ClinicalTrials.gov